Loading stock data…
UTHR
$553.14+8.45 (+1.55%)
Market ClosedLast close Jun 9
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
United Therapeutics Corporation in the Healthcare sector is trading at $553.14 with a market capitalization of $23.3B. Wall Street consensus targets $665.23 (13 analysts), implying a +20.3% move over the next 12 months. The stock is currently near its 52-week high of $609.35, remaining 13.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$553.14
Potential Downside
11.9%
Whystock Fair Value$487.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$665.23+20.3%
Range$516.00 – $750.00
Fundamentals
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$23.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.82%
Volume
Today's trading volume
325,571
Recent News
A Look At United Therapeutics (UTHR) Valuation After Strong Long Term Shareholder Returns
United Therapeutics overview United Therapeutics (UTHR) has drawn investor attention after recent share price moves, with the stock last closing at US$549.87. The company focuses on therapies for chronic and life-threatening diseases, primarily serving patients in the United States. See our latest analysis for United Therapeutics. Recent trading has been choppy, with a 1-day share price return of 0.40% and a 30-day share price return down 7.86%. However, the 1-year total shareholder return of...
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How The Story Around United Therapeutics (UTHR) Is Shifting On Trials Pricing And Valuation
United Therapeutics has seen its fair value estimate adjusted to US$665.23 from US$644.08, a modest shift that puts fresh focus on how the stock is being framed by analysts. Much of the debate centers on how clinical trial outcomes and pricing assumptions could influence long term earnings power and the price targets that follow. As you read on, you will see how to track this evolving narrative and what to watch as views on the stock continue to develop. Analyst Price Targets don't always...
SDZNY or UTHR: Which Is the Better Value Stock Right Now?
SDZNY vs. UTHR: Which Stock Is the Better Value Option?
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.